Recursion Pharmaceuticals Stock

recursionpharma.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $333.7MM

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

Register To Buy and Sell Shares

For more details on financing and valuation for Recursion Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Recursion Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Recursion Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Mason Victors
Chief Technology Officer & Chief Product Officer
Sharath Hegde
Chief Scientific Officer
Ronald Alfa Ph.D
Senior Vice President of Translational Discovery & Chief Evangelist
Blake Borgeson Ph.D
Co-Founder, Scientific Advisor & Board Member
Christopher Gibson Ph.D
Co-Founder, Chief Executive Officer & Board Member
Kevin Leggat
Kevin Lynch Ph.D
Chief Business Officer
Dean Li Ph.D
Board Member & Founder
Tina Larson
Chief Operating Officer
Ben Sukow
Director, Engineering
Heather Kirkby
Chief People Officer

Board Members

Blake Borgeson Ph.D
Zavain Dar
Lux Capital Management
Alaa Halawa
Mubadala Investment Company
Dean Li Ph.D
Zachary Bogue JD
Data Collective
Nan Li
Obvious Ventures
Christopher Gibson Ph.D
Reid Hutchins
Advantage Capital (Saint Louis)
Perry Fell Ph.D
James Hardiman
Data Collective

Frequently Asked Questions About Recursion Pharmaceuticals’ Stock

Can you buy Recursion Pharmaceuticals’ stock?
Recursion Pharmaceuticals is not publicly traded on NYSE or NASDAQ in the U.S. To buy Recursion Pharmaceuticals’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Recursion Pharmaceuticals’ stock?
Yes, you can sell stock of a private company like Recursion Pharmaceuticals. Forge can help you sell your Recursion Pharmaceuticals stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Recursion Pharmaceuticals’ stock price?
Recursion Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access Recursion Pharmaceuticals’ private market stock price with Forge Data.
What is Recursion Pharmaceuticals’ stock ticker symbol?
Recursion Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Recursion Gets Funding For New Drug Discovery With Bayer-led $239M Series D
The new investment provides Recursion with capital to further develop its drug discovery platform and pipeline.
Recursion : Appoints Heather Kirkby as Chief People Officer
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.